Testing S-1 after stomach cancer surgery with or without sequence therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer or cancer where the stomach meets the esophagus, confirmed by biopsy or cell testing
- You had curative surgery with lymph node removal (D2) at this study center, and your pathology stage is stage III
- Scans show no major tumor recurrence or spread at enrollment
- You are 18 to 75 years old, and your functional status is 0 or 1 (you’re fairly active)
- Your blood and organ tests are strong enough for chemotherapy (counts, liver, and kidney values meet limits)
- You can safely take oral medicine (no major absorption problems or recent major stomach/intestinal bleeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Hear when a new Locally Advanced Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.